The availability of FDA-approved potent inhibitors of SRC family PTK such as ponatinib, bosutinib, and dasatinib [Table 1] provides an opportunity to evaluate their clinical impact potential for KMT2A/MLL-R+ leukemias in proof-of-concept clinical trials. This evidence concerns the gene SRC and leukemia.